The use of selenium-containing drugs in the prevention and treatment of complications in patients with COVID-19

Abstract

Objective. To study literature data reflecting the use of selenium (Se) and selenium-containing drugs in the complex prophylaxis and treatment of complications in patients with COVID-19. Material and methods. Data analysis of 37 publications of scientists from Russian Federation, United States of America, People's Republic of China, Great Britain, India, France, Germany, Italy, Sweden, Canada, Brazil, United Arab Emirates, Saudi Arabia, Ireland, Holland, Greece, Australia, Poland, Pakistan, Sudan, Nepal was performed. The authors reflected on the epidemiology, diagnosis, pathogenesis, clinic, risk of acute respiratory distress syndrome, multiple organ failure, cardiovascular complications, mortality in patients with COVID-19, the importance of Se deficiency in the body and the preventive use of selenium-containing drugs in novel coronavirus infection. Results. Low dietary Se intake was associated with the development of acute respiratory distress syndrome in men and women with COVID-19. Deficiencies were associated with increased risk of morbidity and mortality. Organic forms of Se had the best bioavailability. Se had antioxidant, anti-inflammatory, antithrombotic, antiviral, immunomodulatory effects in patients with COVID-19. Conclusions. Thus, control and optimization of the selenium status in population of selenium-deficient areas with addition of Se-enriched food to the diet, as well as SELENBIO for women complex of Russian company "Parapharm" could be one of the directions of prevention and treatment of complications in patients with COVID-19.